Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus AVYCAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus AVYCAZ.
ANCEF vs AVYCAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic